Atherid Secures National Funding for Groundbreaking Drug
- admin960366
- Jul 10
- 1 min read
Atherid Obtains National Funding for Innovative Cardiovascular Disease Drug Candidate
Perth, WA – Atherid Therapeutics has successfully secured major national funding to advance ATH01, a first-in-class drug candidate for treating atherosclerosis, the hardening of arteries that can lead to heart attacks, strokes and lower limb complications leading to amputation.
The funding was awarded through MTPConnect’s Targeted Translation Research Accelerator (TTRA) program, an initiative of the Australian Government’s Medical Research Future Fund. This success has also secured an in-principle cash commitment of $1 million from Western Australia’s Future Health Research and Innovation (FHRI) Fund, through the Major Research and Innovation Application Support (MRIAS) program.
The funded project will focus on scalable GMP manufacturing of ATH01, a critical step required for progressing to clinical trials. This treatment represents a potentially groundbreaking approach to treating cardiovascular disease, the leading cause of death globally.
